Literature DB >> 16440324

Role of osteoblast suppression in multiple myeloma.

James Peter Stewart1, John D Shaughnessy.   

Abstract

Multiple myeloma is the most common form of plasma cell dyscrasia and virtually all cases of myeloma exhibit osteolytic lesions, which result in bone pain, pathological fractures, spinal cord compression, and hypercalcaemia. Malignant plasma cells disrupt the delicate balance between bone formation and bone resorption, which ultimately leads to the debilitating osteolytic lesions. This review focuses principally on mechanisms of osteoblast inhibition by malignant plasma cells with emphasis placed on our experimental findings, which support a model for abnormal Wnt signaling in osteoblast suppression. We describe how excessive amounts of soluble Wnt inhibitors secreted by malignant plasma cells in multiple myeloma could promote osteolytic lesions, tumor growth, suppress hematopoiesis, prevent proper engraftment, and expansion of transplanted stem cells. Finally, we detail current therapies shown to disrupt the interaction between the myeloma cell and the microenvironment, leading to activation of osteoblasts.

Entities:  

Mesh:

Year:  2006        PMID: 16440324     DOI: 10.1002/jcb.20774

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  15 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

2.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Yuping Wang; Sharmin Khan; Mohammad Heidaran; Ajai Pal; Xiaokui Zhang; Shuyang He; Andy Zeitlin; Stewart Abbot; Herbert Faleck; Robert Hariri; John D Shaughnessy; Frits van Rhee; Bijay Nair; Bart Barlogie; Joshua Epstein; Shmuel Yaccoby
Journal:  Stem Cells       Date:  2011-02       Impact factor: 6.277

4.  Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.

Authors:  Shmuel Yaccoby; Wen Ling; Fenghuang Zhan; Ronald Walker; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

5.  Multiple bone lesions and hypercalcemia presented in diffuse large B cell lymphoma: mimicking multiple myeloma?

Authors:  Ping Chen; Bingzong Li; Wenzhuo Zhuang; Haiwen Huang; Hong Zhang; Jinxiang Fu
Journal:  Int J Hematol       Date:  2010-04-09       Impact factor: 2.490

6.  The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.

Authors:  Angela Pennisi; Wen Ling; Xin Li; Sharmin Khan; John D Shaughnessy; Bart Barlogie; Shmuel Yaccoby
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

7.  The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.

Authors:  Angela Pennisi; Xin Li; Wen Ling; Sharmin Khan; Maurizio Zangari; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2009-01       Impact factor: 10.047

8.  Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.

Authors:  Ya-Wei Qiang; John D Shaughnessy; Shmuel Yaccoby
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

9.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

Authors:  Mariateresa Fulciniti; Pierfrancesco Tassone; Teru Hideshima; Sonia Vallet; Puru Nanjappa; Seth A Ettenberg; Zhenxin Shen; Nipun Patel; Yu-Tzu Tai; Dharminder Chauhan; Constantine Mitsiades; Rao Prabhala; Noopur Raje; Kenneth C Anderson; David R Stover; Nikhil C Munshi
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113

Review 10.  Osteoblastogenesis and tumor growth in myeloma.

Authors:  Shmuel Yaccoby
Journal:  Leuk Lymphoma       Date:  2010-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.